Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 320

1.

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group.

Lancet. 2007 Sep 15;370(9591):949-56. Erratum in: Lancet. 2007 Dec 15;370(9604):2004.

PMID:
17869635
[PubMed - indexed for MEDLINE]
2.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
[PubMed - indexed for MEDLINE]
3.

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group.

J Thromb Haemost. 2007 Nov;5(11):2178-85.

PMID:
17764540
[PubMed - indexed for MEDLINE]
4.

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P; BISTRO II Study Group.

J Thromb Haemost. 2005 Jan;3(1):103-11.

PMID:
15634273
[PubMed - indexed for MEDLINE]
5.

Dabigatran: new drug. Continue to use heparin, a better-known option.

[No authors listed]

Prescrire Int. 2009 Jun;18(101):97-9.

PMID:
19637411
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI.

Thromb Haemost. 2009 Jan;101(1):77-85.

PMID:
19132192
[PubMed - indexed for MEDLINE]
7.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
[PubMed - indexed for MEDLINE]
8.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

PMID:
19243718
[PubMed - indexed for MEDLINE]
9.

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V.

J Thromb Haemost. 2004 Sep;2(9):1573-80.

PMID:
15333033
[PubMed - indexed for MEDLINE]
10.

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.

Thromb Res. 2010 Sep;126(3):175-82. doi: 10.1016/j.thromres.2010.03.021. Epub 2010 May 15.

PMID:
20434759
[PubMed - indexed for MEDLINE]
11.

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA.

J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14.

PMID:
18534438
[PubMed - indexed for MEDLINE]
12.

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

McCullagh L, Tilson L, Walsh C, Barry M.

Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000.

PMID:
19803538
[PubMed - indexed for MEDLINE]
13.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

PMID:
19804690
[PubMed - indexed for MEDLINE]
Free Article
14.

Dabigatran etexilate in venous thromboembolism.

Ferrer E.

Drugs Today (Barc). 2009 Oct;45(10):715-24. doi: 1396674/dot.2009.45.10.1425728. Review.

PMID:
20069135
[PubMed - indexed for MEDLINE]
15.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

PMID:
18579811
[PubMed - indexed for MEDLINE]
Free Article
16.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators.

Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.

PMID:
19411100
[PubMed - indexed for MEDLINE]
17.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators.

Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24.

PMID:
18582928
[PubMed - indexed for MEDLINE]
18.

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW.

J Thromb Haemost. 2003 Oct;1(10):2119-30.

PMID:
14521593
[PubMed - indexed for MEDLINE]
19.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
[PubMed - indexed for MEDLINE]
20.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators.

Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.

PMID:
20206776
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk